Related Experiment Video
Updated: May 25, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Preventive pharmacotherapy in type 2 diabetes mellitus
Neeraj Choudhary1, Sanjay Kalra, Ambika Gopalkrishnan Unnikrishnan
1Department of Medicine, Goodhealth Clinic, New Delhi, India.
Indian Journal of Endocrinology and Metabolism
|January 26, 2012
Summary
Preventing type 2 diabetes (T2DM) and cardiovascular disease is crucial due to rising global chronic disease rates. Lifestyle changes are primary, with pharmacotherapy as a secondary option for high-risk individuals.
Area of Science:
- Endocrinology
- Cardiology
- Public Health
Background:
- Global demographic shifts increase chronic non-communicable diseases.
- Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are significant health burdens.
- T2DM complications are increasingly seen in younger populations.
Purpose of the Study:
- To highlight the importance of prevention strategies for T2DM and associated CVD.
- To discuss the role of lifestyle modifications and pharmacotherapy in disease prevention.
- To address the challenges and considerations for long-term preventive treatment.
Main Methods:
- Review of current literature on T2DM and CVD prevention.
- Analysis of demographic trends and disease prevalence.
- Evaluation of pharmacological interventions and lifestyle modification efficacy.
Main Results:
- Preventive strategies are essential to mitigate the growing burden of T2DM and CVD.
- Lifestyle interventions are the cornerstone of prevention.
- Pharmacotherapies like metformin, alpha-glucosidase inhibitors, and pioglitazone show success but face compliance and adverse effect issues.
Conclusions:
- A combined approach of lifestyle changes and, when necessary, pharmacotherapy is recommended.
- Patient motivation for lifestyle changes is paramount.
- Pharmacological management should be considered when lifestyle modifications are insufficient.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...